X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-06-11 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale | $23.50 | -6,115 | 62,284 | -9% | -$143,703 | ||||||
| D | 2026-06-12 | SPRY | Ars Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Officer | S - Sale+OE | $10.00 | -25,000 | 12,176 | -67% | -$250,000 | |||||
2026-06-12 | SPRY | Ars Pharmaceuticals, Inc. | Fitzpatrick Alexander A | GC | S - Sale | $10.00 | -3,355 | 90,910 | -4% | -$33,550 | ||||||
2026-06-12 | ALKS | Alkermes Plc. | Wright Christopher I | Dir | S - Sale | $45.10 | -2,000 | 25,680 | -7% | -$90,200 | ||||||
| DM | 2026-06-10 | CYRX | Cryoport, Inc. | Zecchini Edward J | Chief Digital, Tech Officer | S - Sale+OE | $14.50 | -35,000 | 109,719 | -24% | -$507,563 | |||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale+OE | $27.06 | -1,993 | 39,747 | -5% | -$53,931 | |||||
| DM | 2026-06-10 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $24.20 | -8,519 | 63,443 | -12% | -$206,151 | |||||
| DM | 2026-06-10 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale+OE | $26.32 | -10,278 | 32,259 | -24% | -$270,486 | |||||
2026-06-11 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.17 | +125,000 | 1,193,000 | +12% | +$1,021,225 | ||||||
2026-06-11 | QURE | Uniqure N.V. | O'Keefe Kylie | Chief Customer, Strat Officer | S - Sale | $27.06 | -15,936 | 108,864 | -13% | -$431,228 | ||||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Springhorn Jeremy P. | Dir | S - Sale+OE | $27.06 | -1,993 | 43,251 | -4% | -$53,931 | |||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Post Leonard E | Dir | S - Sale+OE | $27.06 | -1,993 | 35,494 | -5% | -$53,931 | |||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $27.06 | -1,993 | 25,996 | -7% | -$53,931 | |||||
| D | 2026-06-10 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $75.00 | -21,277 | 73,411 | -22% | -$1,595,775 | |||||
| DM | 2026-06-10 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale+OE | $250.00 | -5,000 | 115,580 | -4% | -$1,250,000 | |||||
2026-06-10 | LGND | Ligand Pharmaceuticals Inc | Lamattina John L | Dir | S - Sale | $250.88 | -4,591 | 26,969 | -15% | -$1,151,774 | ||||||
| D | 2026-06-11 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $549.29 | -10,000 | 18,876 | -35% | -$5,492,894 | |||||
| D | 2026-06-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $549.23 | -9,500 | 668,728 | -1% | -$5,217,684 | |||||
| D | 2026-06-11 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Officer | S - Sale+OE | $241.15 | -10,000 | 114,659 | -8% | -$2,411,500 | |||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Jacques Rachelle Suzanne | Dir | S - Sale+OE | $27.06 | -1,993 | 33,903 | -6% | -$53,931 | |||||
| DM | 2026-06-11 | SNDX | Syndax Pharmaceuticals Inc | Botwood Nicholas A.J. | Head of R, D, CMO | S - Sale+OE | $18.07 | -65,515 | 60,885 | -52% | -$1,183,643 | |||||
| D | 2026-06-11 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale+OE | $27.06 | -1,993 | 43,254 | -4% | -$53,931 | |||||
| M | 2026-06-11 | ORKA | Oruka Therapeutics, Inc. | Dambkowski Carl | Dir | S - Sale | $70.13 | -35,000 | 38,743 | -47% | -$2,454,382 | |||||
| M | 2026-06-10 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $68.61 | -388,223 | 1,241,896 | -24% | -$26,634,789 | |||||
2026-06-10 | CMND | Clearmind Medicine Inc. | Hrt Financial LP | 10% | P - Purchase | $0.15 | +2,159,052 | 1,838,075 | -673% | +$330,335 | ||||||
2026-06-11 | CMND | Clearmind Medicine Inc. | Hrt Financial LP | 10% | S - Sale | $0.12 | -225,191 | 1,838,075 | -11% | -$27,698 | ||||||
2026-06-10 | JAZZ | Jazz Pharmaceuticals Plc | Patil Neena M | EVP, GC | S - Sale | $231.83 | -1,200 | 51,549 | -2% | -$278,196 | ||||||
2026-06-11 | INDV | Indivior Pharmaceuticals, Inc. | Heidbreder Christian | Chief Scientific Officer | S - Sale | $38.06 | -18,586 | 227,923 | -8% | -$707,383 | ||||||
2026-06-11 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $0.01 | -2,833,463 | 0 | -100% | -$39,668 | ||||||
2026-06-12 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $13.12 | +3,810,000 | 610,015,809 | +1% | +$49,987,200 | ||||||
2026-06-12 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $13.12 | +3,810,000 | 610,015,809 | +1% | +$49,987,200 | ||||||
| M | 2026-06-10 | AXSM | Axsome Therapeutics, Inc. | Jeffs Roger | Dir | S - Sale | $247.65 | -572 | 58,367 | -1% | -$141,656 | |||||
| M | 2026-06-09 | HOWL | Werewolf Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.37 | -678,226 | 361,229 | -65% | -$253,569 | |||||
2026-06-09 | NUVB | Nuvation Bio Inc. | Mashal Robert | Dir | P - Purchase | $4.73 | +25,000 | 225,000 | +13% | +$118,250 | ||||||
2026-06-05 | NATR | Natures Sunshine Products Inc | Yates Bryant J | EVP, Pres, Europe | S - Sale | $19.90 | -11,968 | 77,446 | -13% | -$238,163 | ||||||
| D | 2026-06-10 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $107.68 | -9,000 | 7,825 | -53% | -$969,120 | |||||
2026-06-09 | STTK | Shattuck Labs, Inc. | Siegall Clay B | Dir | P - Purchase | $4.00 | +62,500 | 318,608 | +24% | +$250,000 | ||||||
| D | 2026-06-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $545.83 | -9,500 | 668,728 | -1% | -$5,185,365 | |||||
| D | 2026-06-09 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $122.81 | -20,000 | 58,117 | -26% | -$2,456,200 | |||||
2026-06-10 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Kung Winston | Dir | S - Sale | $7.91 | -2,026 | 12,140 | -14% | -$16,033 | ||||||
2026-06-10 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Altmeyer Anne | Dir | S - Sale | $7.91 | -2,412 | 7,579 | -24% | -$19,088 | ||||||
2026-06-10 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Jenkins John Kenneth | Dir | S - Sale | $7.91 | -4,800 | 3,833 | -56% | -$37,986 | ||||||
| E | 2026-06-10 | LLY | Eli Lilly & Co | Yuffa Ilya | EVP, Pres, LLY USA, Global Cap | S - Sale | $0.46 | -2,500 | 29,804 | -8% | -$1,151 | |||||
2026-06-10 | LYEL | Lyell Immunopharma, Inc. | Shook David | Chief Medical Officer | S - Sale | $12.64 | -1,977 | 20,923 | -9% | -$24,989 | ||||||
| DM | 2026-06-09 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.16 | -20,918 | 700,000 | -3% | -$128,886 | |||||
| M | 2026-06-08 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.04 | +2,148,823 | 1,040,004 | -194% | +$83,532 | |||||
2026-06-09 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $0.03 | -878,659 | 1,040,004 | -46% | -$28,996 | ||||||
2026-06-09 | ADTX | Aditxt, Inc. | Gong Sandie | 10% | S - Sale | $0.07 | -100,000 | 0 | -100% | -$6,880 | ||||||
| DM | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Mahony Susan | Dir | S - Sale+OE | $241.70 | -600 | 829 | -42% | -$145,017 | |||||
| D | 2026-06-10 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale+OE | $249.00 | -643 | 434,245 | 0% | -$160,107 | |||||
| M | 2026-05-20 | INM | Inmed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% | P - Purchase | $1.57 | +249,227 | 790,979 | +46% | +$391,555 | |||||
2026-06-08 | ANIP | Ani Pharmaceuticals Inc | Haughey Thomas | Dir | S - Sale | $80.88 | -2,000 | 38,878 | -5% | -$161,760 | ||||||
| M | 2026-06-08 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | COB, CEO, Interim CFO, 10% | S - Sale | $4.17 | -22,385 | 350,839 | -6% | -$93,294 | |||||
2026-06-09 | PFE | Pfizer Inc | Damico Jennifer B. | SVP, Controller | S - Sale | $25.70 | -2,000 | 31,397 | -6% | -$51,400 | ||||||
2026-06-08 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale | $271.33 | -136 | 70,629 | 0% | -$36,901 | ||||||
2026-06-08 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $270.42 | -871 | 307,047 | 0% | -$235,539 | ||||||
2026-06-08 | ONC | Beone Medicines Ltd. | Wang Lai | Pres, Global Head of R, D | S - Sale | $269.38 | -1,367 | 2,203,253 | 0% | -$368,247 | ||||||
2026-06-08 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $269.37 | -1,484 | 1,214,078 | 0% | -$399,738 | ||||||
2026-06-08 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $270.56 | -4,940 | 51,577,049 | 0% | -$1,336,548 | ||||||
2026-06-09 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.37 | -76,928 | 300,283 | -20% | -$28,463 | ||||||
| M | 2026-06-09 | MRVI | Maravai Lifesciences Holdings, Inc. | Oreshack Kurt | GC | S - Sale | $5.08 | -50,000 | 335,767 | -13% | -$254,000 | |||||
| D | 2026-06-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $549.32 | -9,500 | 668,728 | -1% | -$5,218,534 | |||||
2026-06-08 | LQDA | Liquidia Corp | Khindri Sanjeev | Chief Development Officer | S - Sale | $65.46 | -4,134 | 67,132 | -6% | -$270,612 | ||||||
| D | 2026-06-08 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $88.53 | -30,000 | 324,879 | -8% | -$2,656,004 | |||||
| M | 2026-06-08 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $64.64 | -220,835 | 1,630,119 | -12% | -$14,273,683 | |||||
2026-06-08 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $94.03 | -6,515 | 492,841 | -1% | -$612,605 | ||||||
2026-06-08 | INDV | Indivior Pharmaceuticals, Inc. | Preblick Ryan | CFO | S - Sale | $37.70 | -36,000 | 284,751 | -11% | -$1,357,200 | ||||||
| D | 2026-06-08 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $93.82 | -5,000 | 47,181 | -10% | -$469,077 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.36 | -11,131 | 440,003 | -2% | -$59,646 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.38 | -49,338 | 518,437 | -9% | -$265,242 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.36 | -9,620 | 303,451 | -3% | -$51,549 | |||||
| M | 2026-06-08 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.36 | -56,344 | 1,374,079 | -4% | -$301,921 | |||||
| D | 2026-06-05 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $80.00 | -3,312 | 180,393 | -2% | -$264,960 | |||||
| D | 2026-06-08 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $547.51 | -10,000 | 18,876 | -35% | -$5,475,045 | |||||
2026-06-05 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | S - Sale | $19.41 | -10,500 | 43,415 | -19% | -$203,820 | ||||||
2026-06-05 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $19.45 | +10,500 | 43,415 | +32% | +$204,260 | ||||||
| D | 2026-06-09 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $67.98 | -3,500 | 153,902 | -2% | -$237,930 | |||||
2026-06-08 | TNXP | Tonix Pharmaceuticals Holding Corp. | Stillwell Richard Newcomb | Dir | P - Purchase | $11.65 | +5,000 | 5,000 | New | +$58,250 | ||||||
2026-06-09 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $11.79 | +5,000 | 29,007 | +21% | +$58,950 | ||||||
| D | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $241.01 | -49,670 | 7,351,729 | -1% | -$11,970,967 | |||||
| D | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | S - Sale+OE | $240.09 | -33,000 | 43,355 | -43% | -$7,922,970 | |||||
| D | 2026-06-08 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $16.94 | +2,000 | 24,500 | +9% | +$33,880 | |||||
2026-06-05 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $34.54 | -10,000 | 51,884 | -16% | -$345,351 | ||||||
| D | 2026-06-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.49 | -9,500 | 668,728 | -1% | -$5,201,110 | |||||
2026-06-05 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,745 | 21,015 | -8% | -$785,250 | ||||||
| D | 2026-06-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $27.30 | -5,222 | 139,763 | -4% | -$142,561 | |||||
2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Patou Gary | Dir | S - Sale | $53.14 | -1,322 | 29,798 | -4% | -$70,251 | ||||||
2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Cannon Gillian | Dir | S - Sale | $53.14 | -1,190 | 1,455 | -45% | -$63,237 | ||||||
2026-06-04 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale | $16.27 | -169,427 | 109,850 | -61% | -$2,756,984 | ||||||
| D | 2026-06-08 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale+OE | $15.44 | -23,214 | 67,894 | -25% | -$358,452 | |||||
| D | 2026-02-13 | CING | Cingulate Inc. | Hargroves Thomas Jeffrey | Dir | P - Purchase | $5.04 | +97,276 | 97,468 | >999% | +$490,271 | |||||
2026-06-04 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.08 | +843,622 | 0 | -100% | +$64,115 | ||||||
2026-06-05 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $0.06 | -735,462 | 0 | -100% | -$45,599 | ||||||
| M | 2026-06-04 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.41 | -105,565 | 377,211 | -22% | -$43,029 | |||||
| M | 2026-06-04 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $67.67 | -80,000 | 5,077,460 | -2% | -$5,413,289 | |||||
2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Dir | S - Sale | $63.91 | -200,000 | 5,033,799 | -4% | -$12,782,059 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Dir | S - Sale | $10.73 | -2,625 | 9,767 | -21% | -$28,166 | ||||||
2026-06-04 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Dir | S - Sale | $10.73 | -2,625 | 263,238 | -1% | -$28,166 | ||||||
| D | 2026-06-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.63 | -9,500 | 668,728 | -1% | -$5,202,436 | |||||
| M | 2026-06-04 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $64.95 | -84,800 | 1,850,954 | -4% | -$5,507,782 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |